<div id="readability-page-1"><div><p>Evolus (EOLS) opened 2026 on the back of a Q4 2025 print that showed US$90.3 million in revenue and basic EPS of roughly US$0.00, supported by net income of US$0.13 million, while the trailing 12 months to Q4 2025 carried basic EPS of US$0.80 in losses on US$297.2 million of revenue and a net loss of US$51.6 million. Over the past few reported quarters, revenue has moved between US$61.1 million and US$90.3 million, while quarterly basic EPS has ranged from a loss of US$0.30 to a slight profit near breakeven. This underscores a business that is generating sales but still working through loss making periods on a trailing basis. For investors, the latest results keep the focus squarely on how quickly margins can firm up and whether recent improvements in quarterly profitability can translate into a more durable earnings profile.</p> <p>See our full analysis for Evolus.</p><p>With the headline numbers on the table, the next step is to see how this earnings story lines up against the widely followed growth and risk narratives around Evolus and where those narratives may need a reset.</p> <p>See what the community is saying about Evolus</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a41c44bd-53bf-4bcc-8af6-b0904b9cf80e/chart/earnings-and-revenue-history/query-ZGF0ZT0yMDI2LTA1LTA2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a41c44bd-53bf-4bcc-8af6-b0904b9cf80e/chart/earnings-and-revenue-history/query-ZGF0ZT0yMDI2LTA1LTA2"/><figcaption>NasdaqGM:EOLS Earnings &amp; Revenue History as at May 2026</figcaption></figure> <h2>Losses Shrink on Trailing Basis</h2> <ul> <li>On a trailing 12 month view to Q4 2025, Evolus reported a net loss of US$51.6 million and basic EPS of US$0.80 in losses on US$297.2 million of revenue, compared with a trailing loss of US$58.6 million and basic EPS of US$0.91 in losses on US$285.8 million of revenue at Q3 2025.</li> <li>What stands out for the bullish view is that these shrinking trailing losses sit alongside forecasts for roughly 73.62% yearly earnings growth and 14.4% yearly revenue growth, yet:     <ul> <li>Trailing revenue has already stepped up from US$248.3 million at Q3 2024 to US$297.2 million at Q4 2025 while losses stayed in the US$50 million to US$60 million range. This fits the idea of a business working toward better margins rather than drifting further into the red.</li> <li>At the same time, the company is still unprofitable and carries negative shareholders’ equity, so the bullish call that earnings could turn positive in the coming years hinges on this loss reduction trend continuing rather than stalling.</li> </ul> </li> </ul> <p>Bulls argue that this kind of loss reduction alongside higher revenue is exactly what a maturing growth story should look like, and they lean on that pattern when they talk about a path to future profitability. <strong>🐂 Evolus Bull Case</strong></p> <h2>Volatile Profit Path Around Q4</h2> <ul> <li>Quarter by quarter, Evolus moved from a basic EPS loss of US$0.30 in Q1 2025 to losses of US$0.27 in Q2 and US$0.24 in Q3, then to roughly breakeven basic EPS of about US$0.00 in Q4 2025, while net income swung from a loss of US$18.9 million in Q1 2025 to a small profit of US$0.13 million in Q4 2025.</li> <li>Bears point out that this bumpy path, especially the shift from a Q3 2025 net loss of US$15.7 million to a near breakeven outcome in Q4, sits uncomfortably next to concerns about a softer aesthetics market and cash pay pressure:     <ul> <li>Critics highlight that peers have reported double digit declines in the HA filler segment and Evolus still had a trailing loss of US$51.6 million at Q4, so one breakeven quarter does not yet address worries about how the model holds up if procedure volumes stay under pressure.</li> <li>On the other hand, the move from multi million dollar quarterly losses through 2024 and early 2025 to a small profit in Q4 2025 means the business is not locked into a single loss level. This slightly softens the most pessimistic view that profitability is out of reach under current conditions.</li> </ul> </li> </ul> <p>Skeptics use this choppy earnings path and the still sizeable trailing loss to argue that Evolus has more to prove before earnings can be treated as durable. <strong>🐻 Evolus Bear Case</strong></p> <h2>Cheap Sales Multiple With Big DCF Gap</h2> <ul> <li>At a share price of US$6.37, the data points to a P/S of about 1.4x versus peers at 5.4x and the US Pharmaceuticals industry at 5.3x, and a cited DCF fair value of US$71.81, which is far above both the current price and the analyst consensus target of US$14.67.</li> <li>Consensus narrative writers see this mix, a low sales multiple and a very high DCF fair value, as both an opportunity and a test of the story around future earnings:     <ul> <li>On one side, the stock trading at a discount to peer and industry P/S levels, alongside trailing revenue of US$297.2 million and shrinking losses, lines up with the idea that investors are not paying much for the potential revenue and earnings growth embedded in the forecasts.</li> <li>On the other, negative shareholders’ equity and higher recent share price volatility show why some investors hesitate to close that gap to either the US$14.67 analyst target or the US$71.81 DCF fair value until the company delivers a longer stretch of consistent profitability.</li> </ul> </li> </ul> <h2>Next Steps</h2> <p>To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Evolus on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.</p> <p>With both cautious and optimistic angles in play, now is a good time to check the underlying data yourself and pressure test the story. Before you decide where you stand, take a close look at the 3 key rewards and 2 important warning signs.</p> <h2>Explore Alternatives</h2> <p>Evolus still reports sizeable trailing losses, negative shareholders’ equity and only a single breakeven quarter. As a result, earnings quality and balance sheet strength remain open questions.</p> <p>If you want ideas where financial footing looks sturdier, especially around debt and equity, take a few minutes to scan the solid balance sheet and fundamentals stocks screener (46 results).</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3>Valuation is complex, but we're here to simplify it.</h3><p>Discover if Evolus might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><p>Access Free Analysis</p></div></div></div>

EOLS

SBIO

IBBQ

LABU

<p>Evolus (EOLS) reported Q4 2025 revenue of US$90.3 million and a basic EPS of approximately US$0.00, with a net income of US$0.13 million. Despite trailing losses of US$51.6 million over the past year, the company shows signs of improving margins and forecasts 73.62% yearly earnings growth. However, concerns remain about the sustainability of profitability amid a challenging aesthetics market. The stock trades at a low P/S of 1.4x compared to peers, indicating potential for growth but also skepticism about future earnings durability.</p>

Evolus (EOLS) Breakeven Q4 EPS Tests Skeptics Of Its Profitability Path